DRG 372 Overview

DRG 372 covers major gastrointestinal disorders and peritoneal infections with Complication or Comorbidity, including significant abdominal infections, severe inflammatory bowel disease exacerbations, and complex gastrointestinal surgical complications that require inpatient medical or surgical management. This Diagnosis-Related Group is important for Medicare payment because the presence of a Complication or Comorbidity raises relative resource use and payment compared with cases without such comorbidity, affecting hospital reimbursement and case-mix classification. Accurate documentation of diagnoses, procedures, and complications determines assignment to this Diagnosis-Related Group and thereby influences payment for inpatient stays.

• Acute surgical and critical care intervention trials: randomized or pragmatic studies evaluating timing, technique, and perioperative management for patients with major gastrointestinal disorders (such as perforated viscus, ischemic bowel, or severe diverticulitis) and peritoneal infections who require emergency laparotomy or source-control procedures. These trials enroll adults presenting with acute abdomen and sepsis, comparing approaches like damage-control surgery versus definitive repair, variations in peritoneal lavage or drain strategies, and optimized resuscitation protocols during the immediate inpatient period. Results inform surgeons, intensivists, and payers about outcomes tied to length of stay, complication rates, and resource intensity that drive DRG utilization and reimbursement for high-acuity admissions.
• Comparative effectiveness and antimicrobial stewardship studies: observational cohorts and randomized trials comparing antibiotic selection, duration, and route (IV-to-oral switch) for complicated intra-abdominal infections and peritonitis in medically complex patients, including those with coexisting organ dysfunction or immunosuppression. These studies focus on clinical cure, recurrence, antimicrobial resistance patterns, and adverse events across heterogeneous inpatient populations receiving source control plus antimicrobial therapy. Evidence from these investigations guides inpatient antibiotic protocols and stewardship programs that can reduce readmissions, antibiotic-related costs, and downstream expenditures important to hospital case-mix management and payer risk adjustments.
• Post-discharge outcomes and care-transition research: prospective studies and quality-improvement trials assessing early discharge planning, outpatient parenteral antimicrobial therapy (OPAT) pathways, rehabilitation needs, and readmission prevention for survivors of major GI disorders and peritoneal infections who had CC-level complications. Patient populations include those discharged with drains, wounds, or ongoing nutritional support; interventions evaluate coordinated home health, telemonitoring, and standardized follow-up to reduce complications and unplanned returns. Findings are relevant to providers and payers because improved transitions can shorten inpatient stays, lower readmission rates, and optimize total episode-of-care costs associated with this high-resource DRG.